[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-patients":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100522195","the-effect-of-progressive-relaxation-exercise-on-anxiety-and-quality-of-life-of-diabetic-patients-100522195",false,"NCT06079463","The Effect of Progressive Relaxation Exercise on Anxiety and Quality of Life of Diabetic Patients","Determining the Effect of Progressive Relaxation Exercise on Anxiety and Quality of Life in Diabetes Patients","Inclusion Criteria:\n\n* Diabetic patients who will be treated in the Internal Medicine Service who want to participate in the study voluntarily.\n* Patients over the age of 18\n\nExclusion Criteria:\n\n* Patients who do not want to participate in the study.\n* Patients who are unable to perform the progressive relaxation exercise (amputation, etc.).\n* Pregnant or breastfeeding patients",true,"ALL","18 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"NA","Purpose of the study: The study aimed to direct the anxiety and quality of life of progressive movement exercise in diabetic patients.\n\nType of research: A randomized controlled pre-test-post-test study was planned with the aim of directing progressive movement exercise on anxiety and quality of life in diabetics.\n\nresearch questions Q1: Does progressive movement exercise have an effect on diabetic anxiety and quality of life? Population of the Research and Sample Selection: The home of the research will be the diabetes windows to the internal service on data collection. G-power 3.1 analysis program environment to calculate large sample size. Sampling of the research; With 0.61% effect sizes, 0.05% error level, 95% confidence interval and 80% power to show the universe, 52 people took part in the experimental motivations (phased training exercises group) and 52 people took part in the control slots, for a total of 104 people. Sample selection criteria patients are randomized using the Random Integer Generator method from the Numbers subheading on the Random.org website. In randomization, aspects will be collected representatively of 1 experimental group and 2 control groups.",[27],"Diabetic Patients",[29,30,31,32],"Anxiety","Diabetes","Exercise","Quality of Life","RECRUITING","2024-08-28",{"date":36,"type":37},"2024-08-29","ACTUAL",{"date":39,"type":37},"2023-10-10",{"date":41,"type":21},"2025-01-01",{"name":43,"class":44},"Kahramanmaraş İstiklal University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100558952","phase-4-effect-of-oral-semaglutide-on-epicardial-and-pericoronary-adipose-tissues-in-type-2-diabetes-after-myocardial-infarction-100558952","NCT06557811","Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction","Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction: a Randomized and Double-blind Clinical Trial","SemaFatCard","Inclusion Criteria:\n\nMale or female patient aged 50 years or older at the time of screening, diagnosed with type 2 diabetes and with a previous acute myocardial infarction more than 2 and less than 9 months ago, with the following conditions:\n\n1. Signed Informed Consent Form.\n2. BMI ≥ 25 and \\\u003C 40 kg\u002Fm².\n3. The following glucose-lowering agents are permitted: any insulin, insulin analogs, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, and SGLT-2 inhibitors (iSGLT2).\n4. Patients using iSGLT2 will not be excluded because they receive this medication at no cost at InCor with benefits for the treatment of type 2 diabetes. Furthermore, there would be an impact on ethical issues and the control of this prescription in other clinics. Thus, we will list the patients using SGLT2 inhibitors and statistically evaluate the comparison with the group that did not use this medication.\n\nExclusion Criteria:\n\n1. Patients with type 1 diabetes.\n2. Type 2 diabetes currently or previously treated (within 90 days prior to screening) with any GLP-1RA and DPP-4 inhibitor.\n3. Those not properly treated for previously diagnosed hypothyroidism.\n4. Diagnosed with NYHA class IV heart failure.\n5. Myocardial infarction more than 9 months after diagnosis.\n6. Any of the following: myocardial infarction, stroke, or hospitalization for unstable angina or transient ischemic attack within 60 days before screening.\n7. Any contraindication present in the package insert for the use of GLP1-RA or Oral Semaglutide.\n8. Desire to become pregnant.\n9. Previous history of pancreatitis (acute or chronic).\n10. Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.\n11. History of major surgical procedures involving the stomach, potentially affecting the absorption of the test product (e.g., subtotal and total gastrectomy, vertical gastrectomy, gastric bypass surgery).\n12. Planned and known coronary, carotid, or peripheral arterial revascularization on the day of screening.\n13. Chronic or intermittent hemodialysis, peritoneal dialysis, or severe renal insufficiency (corresponding to eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) - due to CT specifications reported below.\n\n    History or presence of malignant neoplasm in the last 5 years (except basal cell and squamous cell skin cancer and carcinoma in situ).\n14. History of diabetic ketoacidosis.\n15. Participation in another clinical trial investigating a drug.\n16. Participation in a clinical trial specifically evaluating stent(s) will be allowed.\n17. Uncontrolled systemic arterial hypertension with multiple antihypertensive agents.\n18. Any disorder that, in the opinion of the researcher, may compromise patient safety or protocol compliance.","50 Years",{"count":56,"type":21},88,[58],"PHASE4","The goal of this clinical trial is to investigate the ability of oral semaglutide to reduce pericardial and perivascular fat as well as coronary plaque in type 2 diabetic patients after acute myocardial infarction. Patients of both sexes, aged 50 years or older, diagnosed with type 2 diabetes and with a previous acute myocardial infarction between more than 2 and less than 9 months ago, will be included.\n\nThe primary objective is to investigate the ability of oral semaglutide to reduce pericardial and perivascular fat in type 2 diabetics after myocardial infarction.\n\nThe primary outcome will be composed of three measures:\n\nMeasurement of pericardial adipose tissue at 180 days; Measurement of the perivascular adipose tissue attenuation index at 180 days; Measurement of the fat attenuation index at 180 days.\n\nTo assess the degree of epicardial and perivascular fat attenuation, coronary artery computed tomography will be performed, and to evaluate the left ventricular ejection fraction, transthoracic echocardiography will be conducted.\n\nOral semaglutide may reduce pericardial and\u002For perivascular fat in diabetics after acute myocardial infarction.",[27,61],"Acute Myocardial Infarction",[30,63,64],"Acute myocardial infarction","Oral Semaglutide","NOT_YET_RECRUITING","2024-08-22",{"date":68,"type":37},"2024-08-26",{"date":70,"type":21},"2024-09-01",{"date":72,"type":21},"2026-09-01",{"name":74,"class":44},"University of Sao Paulo General Hospital"]